VAXIL: SHARE CONSOLIDATION

Core Points - Vaxil Bio Ltd. will consolidate its common shares at a ratio of one post-consolidation share for every fifty pre-consolidation shares [1][2] - The effective date for the consolidation is set for May 15, 2025, with trading on a post-consolidation basis expected to commence on or about the same date [2] - The total number of outstanding common shares will decrease from approximately 136,978,973 to about 2,739,579 post-consolidation [3] Shareholder Information - Registered shareholders will receive letters of transmittal and must deposit their share certificates with Computershare Investor Services Inc. [4] - Non-registered shareholders should check with their intermediaries for specific procedures regarding the consolidation [4] Financial Instruments Adjustment - Outstanding stock options and share purchase warrants will be adjusted according to the consolidation ratio, affecting their respective exercise prices [5] Company Overview - Vaxil is an Israeli biotech company focused on immunotherapy, particularly its lead product ImMucin™, which has completed a Phase 1/2 clinical trial for multiple myeloma and received orphan drug status from the FDA and EMA [6] - The company is currently evaluating whether to continue developing ImMucin™ or explore other business opportunities to enhance shareholder value [6]